Tumor-associated macrophages in nanomaterial-based anti-tumor therapy: as target spots or delivery platforms
Targeting tumor-associated macrophages (TAMs) has emerged as a promising approach in cancer therapy. This article provides a comprehensive review of recent advancements in the field of nanomedicines targeting TAMs. According to the crucial role of TAMs in tumor progression, strategies to inhibit mac...
| Main Authors: | , , , , , , , |
|---|---|
| Format: | Article |
| Language: | English |
| Published: |
Frontiers Media S.A.
2023-08-01
|
| Series: | Frontiers in Bioengineering and Biotechnology |
| Subjects: | |
| Online Access: | https://www.frontiersin.org/articles/10.3389/fbioe.2023.1248421/full |
| _version_ | 1811153930947657728 |
|---|---|
| author | Jixuan Zheng Jinting Jiang Yicheng Pu Tingrui Xu Jiantong Sun Qiang Zhang Ling He Xiao Liang |
| author_facet | Jixuan Zheng Jinting Jiang Yicheng Pu Tingrui Xu Jiantong Sun Qiang Zhang Ling He Xiao Liang |
| author_sort | Jixuan Zheng |
| collection | DOAJ |
| description | Targeting tumor-associated macrophages (TAMs) has emerged as a promising approach in cancer therapy. This article provides a comprehensive review of recent advancements in the field of nanomedicines targeting TAMs. According to the crucial role of TAMs in tumor progression, strategies to inhibit macrophage recruitment, suppress TAM survival, and transform TAM phenotypes are discussed as potential therapeutic avenues. To enhance the targeting capacity of nanomedicines, various approaches such as the use of ligands, immunoglobulins, and short peptides are explored. The utilization of live programmed macrophages, macrophage cell membrane-coated nanoparticles and macrophage-derived extracellular vesicles as drug delivery platforms is also highlighted, offering improved biocompatibility and prolonged circulation time. However, challenges remain in achieving precise targeting and controlled drug release. The heterogeneity of TAMs and the variability of surface markers pose hurdles in achieving specific recognition. Furthermore, the safety and clinical applicability of these nanomedicines requires further investigation. In conclusion, nanomedicines targeting TAMs hold great promise in cancer therapy, offering enhanced specificity and reduced side effects. Addressing the existing limitations and expanding our understanding of TAM biology will pave the way for the successful translation of these nano-therapies into clinical practice. |
| first_indexed | 2024-03-12T14:34:22Z |
| format | Article |
| id | doaj.art-850eebf4c0694daca250fa671c100fb7 |
| institution | Directory Open Access Journal |
| issn | 2296-4185 |
| language | English |
| last_indexed | 2024-03-12T14:34:22Z |
| publishDate | 2023-08-01 |
| publisher | Frontiers Media S.A. |
| record_format | Article |
| series | Frontiers in Bioengineering and Biotechnology |
| spelling | doaj.art-850eebf4c0694daca250fa671c100fb72023-08-17T11:50:22ZengFrontiers Media S.A.Frontiers in Bioengineering and Biotechnology2296-41852023-08-011110.3389/fbioe.2023.12484211248421Tumor-associated macrophages in nanomaterial-based anti-tumor therapy: as target spots or delivery platformsJixuan Zheng0Jinting Jiang1Yicheng Pu2Tingrui Xu3Jiantong Sun4Qiang Zhang5Ling He6Xiao Liang7Key Laboratory of Birth Defects and Related Diseases of Women and Children, Ministry of Education, West China Second Hospital, West China School of Medicine, West China School of Pharmacy, Sichuan University, Chengdu, ChinaKey Laboratory of Birth Defects and Related Diseases of Women and Children, Ministry of Education, West China Second Hospital, West China School of Medicine, West China School of Pharmacy, Sichuan University, Chengdu, ChinaKey Laboratory of Birth Defects and Related Diseases of Women and Children, Ministry of Education, West China Second Hospital, West China School of Medicine, West China School of Pharmacy, Sichuan University, Chengdu, ChinaKey Laboratory of Birth Defects and Related Diseases of Women and Children, Ministry of Education, West China Second Hospital, West China School of Medicine, West China School of Pharmacy, Sichuan University, Chengdu, ChinaKey Laboratory of Birth Defects and Related Diseases of Women and Children, Ministry of Education, West China Second Hospital, West China School of Medicine, West China School of Pharmacy, Sichuan University, Chengdu, ChinaHospital of Chengdu University of Traditional Chinese Medicine, Chengdu, ChinaHospital of Chengdu University of Traditional Chinese Medicine, Chengdu, ChinaKey Laboratory of Birth Defects and Related Diseases of Women and Children, Ministry of Education, West China Second Hospital, West China School of Medicine, West China School of Pharmacy, Sichuan University, Chengdu, ChinaTargeting tumor-associated macrophages (TAMs) has emerged as a promising approach in cancer therapy. This article provides a comprehensive review of recent advancements in the field of nanomedicines targeting TAMs. According to the crucial role of TAMs in tumor progression, strategies to inhibit macrophage recruitment, suppress TAM survival, and transform TAM phenotypes are discussed as potential therapeutic avenues. To enhance the targeting capacity of nanomedicines, various approaches such as the use of ligands, immunoglobulins, and short peptides are explored. The utilization of live programmed macrophages, macrophage cell membrane-coated nanoparticles and macrophage-derived extracellular vesicles as drug delivery platforms is also highlighted, offering improved biocompatibility and prolonged circulation time. However, challenges remain in achieving precise targeting and controlled drug release. The heterogeneity of TAMs and the variability of surface markers pose hurdles in achieving specific recognition. Furthermore, the safety and clinical applicability of these nanomedicines requires further investigation. In conclusion, nanomedicines targeting TAMs hold great promise in cancer therapy, offering enhanced specificity and reduced side effects. Addressing the existing limitations and expanding our understanding of TAM biology will pave the way for the successful translation of these nano-therapies into clinical practice.https://www.frontiersin.org/articles/10.3389/fbioe.2023.1248421/fulltumor-associated macrophagenanoparticletumor micorenvironment targetingnanoparticle deliveryantitumor therapy |
| spellingShingle | Jixuan Zheng Jinting Jiang Yicheng Pu Tingrui Xu Jiantong Sun Qiang Zhang Ling He Xiao Liang Tumor-associated macrophages in nanomaterial-based anti-tumor therapy: as target spots or delivery platforms Frontiers in Bioengineering and Biotechnology tumor-associated macrophage nanoparticle tumor micorenvironment targeting nanoparticle delivery antitumor therapy |
| title | Tumor-associated macrophages in nanomaterial-based anti-tumor therapy: as target spots or delivery platforms |
| title_full | Tumor-associated macrophages in nanomaterial-based anti-tumor therapy: as target spots or delivery platforms |
| title_fullStr | Tumor-associated macrophages in nanomaterial-based anti-tumor therapy: as target spots or delivery platforms |
| title_full_unstemmed | Tumor-associated macrophages in nanomaterial-based anti-tumor therapy: as target spots or delivery platforms |
| title_short | Tumor-associated macrophages in nanomaterial-based anti-tumor therapy: as target spots or delivery platforms |
| title_sort | tumor associated macrophages in nanomaterial based anti tumor therapy as target spots or delivery platforms |
| topic | tumor-associated macrophage nanoparticle tumor micorenvironment targeting nanoparticle delivery antitumor therapy |
| url | https://www.frontiersin.org/articles/10.3389/fbioe.2023.1248421/full |
| work_keys_str_mv | AT jixuanzheng tumorassociatedmacrophagesinnanomaterialbasedantitumortherapyastargetspotsordeliveryplatforms AT jintingjiang tumorassociatedmacrophagesinnanomaterialbasedantitumortherapyastargetspotsordeliveryplatforms AT yichengpu tumorassociatedmacrophagesinnanomaterialbasedantitumortherapyastargetspotsordeliveryplatforms AT tingruixu tumorassociatedmacrophagesinnanomaterialbasedantitumortherapyastargetspotsordeliveryplatforms AT jiantongsun tumorassociatedmacrophagesinnanomaterialbasedantitumortherapyastargetspotsordeliveryplatforms AT qiangzhang tumorassociatedmacrophagesinnanomaterialbasedantitumortherapyastargetspotsordeliveryplatforms AT linghe tumorassociatedmacrophagesinnanomaterialbasedantitumortherapyastargetspotsordeliveryplatforms AT xiaoliang tumorassociatedmacrophagesinnanomaterialbasedantitumortherapyastargetspotsordeliveryplatforms |